亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

医学 伊布替尼 慢性淋巴细胞白血病 内科学 队列 中性粒细胞减少症 胃肠病学 布鲁顿酪氨酸激酶 不利影响 肿瘤科 白血病 酪氨酸激酶 化疗 受体
作者
Jennifer A. Woyach,Ian W. Flinn,Farrukh T. Awan,Herbert Eradat,Danielle M. Brander,Michael Tees,Sameer A. Parikh,Tycel Phillips,Razi Ghori,Nishitha Reddy,Mohammed Z.H. Farooqui,John C. Byrd,Deborah M. Stephens
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 7004-7006 被引量:33
标识
DOI:10.1182/blood-2022-163596
摘要

Background: Bruton tyrosine kinase inhibitors (BTKis) have transformed the treatment landscapes of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and certain B-cell neoplasms. However, the most common mechanism of resistance is due to mutations to BTK at the cysteine binding site (C481). Nemtabrutinib (MK-1026, formerly ARQ-531) is a noncovalent, potent inhibitor of both wild-type and ibrutinib-resistant C481S-mutated BTK. Initial results from the phase 1/2 BELLWAVE-001 study (NCT03162536) showed nemtabrutinib had a manageable safety profile and promising antitumor activity in heavily pretreated patients (pts) with relapsed or refractory (R/R) CLL/SLL, including pts whose disease progressed after prior covalent BTKis (Woyach et al. Blood. 2021;138:392). We present updated efficacy for all pts with CLL/SLL treated with nemtabrutinib 65 mg and safety for all pts with hematological malignancies who were treated with nemtabrutinib at the 65-mg dose. Methods: In this open-label, single-arm, phase 1/2 study, 9 expansion cohorts were initiated after determination of the preliminary nemtabrutinib recommended phase 2 dose (RP2D). Eligible pts with CLL/SLL were enrolled in cohort A (R/R CLL/SLL, with ≥2 prior therapies, including covalent BTKis, with documented C481 mutation), cohort B (R/R CLL/SLL with ≥2 prior therapies, intolerant to a BTKi, without C481 mutation), a dose-expansion group, or cohort I (food effect). Primary end points were ORR (per 2018 IWCLL criteria, by investigator), safety, and RP2D for pts with CLL/SLL. Secondary end points were DOR (including partial response [PR] with lymphocytosis), PFS, and safety. Efficacy analysis included CLL/SLL pts treated with nemtabrutinib 65-mg once-daily dose and safety included all pts with hematological malignancies who were treated with the nemtabrutinib 65-mg dose. Results: A total of 112 pts were enrolled and were treated with nemtabrutinib 65 mg once daily: 57 had CLL/SLL, 46 had B-cell non-Hodgkin lymphoma (NHL), 6 had Waldenstrom's macroglobulinemia, and 3 had a diagnosis of "other.” Among the 57 pts with CLL/SLL enrolled and treated with nemtabrutinib 65 mg (cohort A, n = 25; cohort B, n = 10; dose escalation, n = 13; cohort I, n = 9); median age was 66.0 years; 16 pts (28%) were female, and 50 (88%) had ECOG PS ≤1. Median (range) number of prior therapies was 4 (1-18); 54 pts (95%) had prior BTKi therapy; 24 (42%) had prior BTKi and BCL2i therapy. In addition, 36 pts (63%) had C481S-mutated BTK; 18 (32%) had TP53 mutation; 19 (33%) had del(17p); and 30 (53%) had unmutated IGHV. Of pts with CLL/SLL, 39 (68%) discontinued, most commonly because of clinical disease progression [PD] and "other” causes (10 [18%] each); 8 (14%) discontinued owing to adverse events (AEs). Among the 24 pts with CLL/SLL who received prior BTKis and BCL-2is, 19 (33%) discontinued, most commonly because of clinical PD and other causes (6 [11%] each) and AEs (4 [7%]). At data cutoff (April 08, 2022), median (range) follow-up for pts with CLL/SLL was 8.1 months (0.1-38.8); 32 pts had objective response (ORR, 56% [95% CI, 42-69]; complete response, 2; PR, 15; PR with residual lymphocytosis, 15). Among the 32 pts who responded, median DOR was 24.4 months (95% CI, 13.9-not evaluable [NE]); median PFS was 26.3 months (95% CI, 10.1-NE). Efficacy by key subgroups is presented in the table. Among all pts with B-cell malignancies treated with nemtabrutinib at the 65-mg dose (N = 112) included in the safety analysis, 82 (73%) had any-grade treatment-related AEs (TRAEs), most common (≥10%) were dysgeusia (21%); decreased neutrophils (20%); fatigue (13%); nausea and decreased platelets (12%, each); and diarrhea and hypertension (10%, each). Grade 3 or 4 TRAEs occurred in 45 pts (40%); most common (≥5%) were decreased neutrophils (17%) and decreased platelets and lymphocytosis (5%, each). Treatment-related discontinuations occurred in 15 pts (13%). No deaths were attributed to treatment. Conclusion: Nemtabrutinib 65 mg continued to show promising and durable antitumor activity with a manageable safety profile in a highly relapsed/refractory population who had prior therapy with novel agents. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被撩寮采纳,获得10
刚刚
康子浩发布了新的文献求助10
3秒前
多情嫣然完成签到,获得积分10
7秒前
8秒前
ZaZa完成签到,获得积分10
8秒前
11秒前
summerer发布了新的文献求助10
17秒前
Lucas的应助被科研通管家采纳,获得10
18秒前
852的应助被科研通管家采纳,获得10
19秒前
共享精神的应助被科研通管家采纳,获得10
19秒前
殷宵箫发布了新的文献求助10
19秒前
英姑的应助被科研通管家采纳,获得10
19秒前
含蓄的芝麻完成签到,获得积分10
21秒前
ADAB0002完成签到,获得积分10
22秒前
果冻完成签到 ,获得积分10
23秒前
23秒前
vfdhjng完成签到,获得积分20
25秒前
25秒前
可爱的函函的应助被lx采纳,获得10
27秒前
28秒前
华仔的应助被怡宝采纳,获得10
29秒前
summerer发布了新的文献求助20
30秒前
31秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
31秒前
费洛蒙漩涡完成签到,获得积分10
32秒前
孤独孤风完成签到,获得积分10
32秒前
苹果颖完成签到,获得积分10
33秒前
lx完成签到,获得积分10
34秒前
35秒前
35秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
35秒前
36秒前
鱼鱼鱼完成签到,获得积分10
38秒前
lx发布了新的文献求助10
40秒前
40秒前
顺心尔冬完成签到,获得积分10
40秒前
41秒前
康子浩发布了新的文献求助10
41秒前
cong发布了新的文献求助10
43秒前
科研通AI6.2的应助被追寻芷采纳,获得10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622